MétaCan
Menu
Back to cohort
Record W4318922869 · doi:10.1212/wnl.0000000000201626

<i>DMD</i> Genotypes and Motor Function in Duchenne Muscular Dystrophy

2023· review· en· W4318922869 on OpenAlexfundno aff
Francesco Muntoni, James Signorovitch, Gautam Sajeev, H. Clifford Lane, Madeline Jenkins, Ibrahima Dieye, Susan J. Ward, Craig M. McDonald, Nathalie Goemans, E. Niks, Brenda Wong, Laurent Servais, Volker Straub, Michela Guglieri, Imelda J. M. de Groot, Mary Chesshyre, Cuixia Tian, Adnan Y. Manzur, Eugenio Mercuri, Annemieke Aartsma‐Rus

Bibliographic record

VenueNeurology · 2023
Typereview
Languageen
FieldMedicine
TopicNeurogenetic and Muscular Disorders Research
Canadian institutionsnot available
FundersDaiichi Sankyo EuropeGreat Ormond Street Institute of Child HealthSanofi GenzymeUniversity Hospitals Bristol NHS Foundation TrustItalfarmacoUniversity of OxfordProQR TherapeuticsUniversity of NottinghamHospital for Sick ChildrenLeids Universitair Medisch CentrumEli Lilly and CompanyRadboud UniversiteitUniversiteit LeidenNewcastle UniversityUniversity College LondonZonMwPTC TherapeuticsUniversity of CambridgeNational Institute on Disability, Independent Living, and Rehabilitation ResearchNational Institute for Health and Care ResearchU.S. Department of DefenseUniversity Hospitals Plymouth NHS TrustSilence TherapeuticsAudentes TherapeuticsRadboud Universitair Medisch CentrumGreat Ormond Street Hospital for ChildrenNHS Greater Glasgow and ClydeCincinnati Children's Hospital Medical CenterSarepta TherapeuticsUniversity Hospital Southampton NHS Foundation TrustOxford University Hospitals NHS Foundation TrustNational Institute of Arthritis and Musculoskeletal and Skin DiseasesAstellas PharmaEisaiFibroGenCytokineticsParent Project Muscular DystrophyCambridge University HospitalsVertex PharmaceuticalsNational Institutes of HealthUniversity Hospitals Birmingham NHS Foundation TrustBioMarin PharmaceuticalBiogenNational Institute on Disability and Rehabilitation ResearchPfizerBioClinicaGilead SciencesSanofiBristol-Myers SquibbDuchenne Parent ProjectAveXisGlaxoSmithKline
KeywordsDuchenne muscular dystrophyMedicineGenotypeConfoundingAmbulatoryClinical trialInternal medicinePediatricsGeneticsBiology

Abstract

fetched live from OpenAlex

BACKGROUND AND OBJECTIVES: genotype class. This avoids confounding of drug efficacy by genotype effects but also shrinks the pool of eligible controls, increasing challenges for trial enrollment in this already rare disease. To evaluate the suitability of genotypically unmatched controls in DMD, we quantified effects of genotype class on 1-year changes in motor function endpoints used in clinical trials. METHODS: More than 1,600 patient-years of follow-up (>700 patients) were studied from 6 real-world/natural history data sources (UZ Leuven, PRO-DMD-01 shared by CureDuchenne, iMDEX, North Star UK, Cincinnati Children's Hospital Medical Center, and the DMD Italian Group), with genotypes classified as amenable to skipping exons 44, 45, 51, or 53, or other skippable, nonsense, and other mutations. Associations between genotype class and 1-year changes in North Star Ambulatory Assessment total score (ΔNSAA) and in 10-m walk/run velocity (Δ10MWR) were studied in each data source with and without adjustment for baseline prognostic factors. RESULTS: The studied genotype classes accounted for approximately 2% of variation in ΔNSAA outcomes after 12 months, whereas other prognostic factors explained >30% of variation in large data sources. Based on a meta-analysis across all data sources, pooled effect estimates for the studied skip-amenable mutation classes were all small in magnitude (<2 units in ΔNSAA total score in 1-year follow up), smaller than clinically important differences in NSAA, and were precisely estimated with standard errors <1 unit after adjusting for nongenotypic prognostic factors. DISCUSSION: These findings suggest the viability of trial designs incorporating genotypically mixed or unmatched controls for up to 12 months in duration for motor function outcomes, which would ease recruitment challenges and reduce numbers of patients assigned to placebos. Such trial designs, including multigenotype platform trials and hybrid designs, should ensure baseline balance between treatment and control groups for the most important prognostic factors, while accounting for small remaining genotype effects quantified in this study.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.007
metaresearch head score (Gemma)0.011
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.007
Threshold uncertainty score0.036

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0070.011
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.003
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.049
GPT teacher head0.333
Teacher spread0.284 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations38
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueNeurologySame topicNeurogenetic and Muscular Disorders ResearchFrench-language works237,207